K Pritchard-Jones

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. ncbi request reprint Multiple pathways to Wilms tumor: how much is genetic?
    Kathy Pritchard-Jones
    Children s Department, Royal Marsden Hospital and Institute of Cancer Research Downs Road, Sutton, Surrey, United Kingdom
    Pediatr Blood Cancer 47:232-4. 2006
  2. ncbi request reprint Older age is an adverse prognostic factor in stage I, favorable histology Wilms' tumor treated with vincristine monochemotherapy: a study by the United Kingdom Children's Cancer Study Group, Wilm's Tumor Working Group
    K Pritchard-Jones
    Department of Paediatric Oncology, Royal Marsden Hospital Institute of Cancer Research, Brookes Lawley Bldg, Cotswold Rd, Sutton, Surrey, SM2 5NG, United Kingdom
    J Clin Oncol 21:3269-75. 2003
  3. doi request reprint Clinical trials for children with cancer in Europe - still a long way from harmonisation: a report from SIOP Europe
    K Pritchard-Jones
    The Institute of Cancer Research and The Royal Marsden Hospital, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Eur J Cancer 44:2106-11. 2008
  4. doi request reprint Improving recruitment to clinical trials for cancer in childhood
    Kathy Pritchard-Jones
    Section of Paediatric Oncology Children s Unit, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    Lancet Oncol 9:392-9. 2008
  5. ncbi request reprint Success of clinical trials in childhood Wilms' tumour around the world
    K Pritchard-Jones
    Institute of Cancer Research Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK
    Lancet 364:1468-70. 2004
  6. pmc What can we learn from geographical comparisons of childhood cancer survival?
    K Pritchard-Jones
    Section of Paediatric Oncology, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Br J Cancer 96:1493-7. 2007
  7. ncbi request reprint Cancer in children and adolescents in Europe: developments over 20 years and future challenges
    K Pritchard-Jones
    Section of Paediatric Oncology, Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK
    Eur J Cancer 42:2183-90. 2006
  8. ncbi request reprint In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line
    H A Cocker
    CRC Centre for Cancer Therapeutics, The Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom
    Clin Cancer Res 7:3193-8. 2001
  9. ncbi request reprint Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour
    R Natrajan
    Paediatric Oncology, Institute of Cancer Research Royal Marsden NHS Trust, Sutton, UK
    J Pathol 211:52-9. 2007
  10. pmc Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma
    J Anderson
    Section of Paediatric Oncology, Institute of Cancer Research, Sutton, Surrey, UK
    Neoplasia 1:340-8. 1999

Detail Information

Publications67

  1. ncbi request reprint Multiple pathways to Wilms tumor: how much is genetic?
    Kathy Pritchard-Jones
    Children s Department, Royal Marsden Hospital and Institute of Cancer Research Downs Road, Sutton, Surrey, United Kingdom
    Pediatr Blood Cancer 47:232-4. 2006
  2. ncbi request reprint Older age is an adverse prognostic factor in stage I, favorable histology Wilms' tumor treated with vincristine monochemotherapy: a study by the United Kingdom Children's Cancer Study Group, Wilm's Tumor Working Group
    K Pritchard-Jones
    Department of Paediatric Oncology, Royal Marsden Hospital Institute of Cancer Research, Brookes Lawley Bldg, Cotswold Rd, Sutton, Surrey, SM2 5NG, United Kingdom
    J Clin Oncol 21:3269-75. 2003
    ....
  3. doi request reprint Clinical trials for children with cancer in Europe - still a long way from harmonisation: a report from SIOP Europe
    K Pritchard-Jones
    The Institute of Cancer Research and The Royal Marsden Hospital, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Eur J Cancer 44:2106-11. 2008
    ..Issues raised at the recent conference held to reappraise the operation of the Directive are summarised to emphasise the particular issues for trials in children with cancer...
  4. doi request reprint Improving recruitment to clinical trials for cancer in childhood
    Kathy Pritchard-Jones
    Section of Paediatric Oncology Children s Unit, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    Lancet Oncol 9:392-9. 2008
    ..The introduction of new paediatric regulations in Canada and the USA and Europe should encourage manufacturers of new anticancer drugs to lend support to clinical trials of cancer in childhood...
  5. ncbi request reprint Success of clinical trials in childhood Wilms' tumour around the world
    K Pritchard-Jones
    Institute of Cancer Research Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK
    Lancet 364:1468-70. 2004
  6. pmc What can we learn from geographical comparisons of childhood cancer survival?
    K Pritchard-Jones
    Section of Paediatric Oncology, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Br J Cancer 96:1493-7. 2007
    ..Participation in international clinical trials coincided with rapid gains in survival for hepatoblastoma. This exemplifies the potential benefits of international collaborative clinical research, particularly for rare subgroups...
  7. ncbi request reprint Cancer in children and adolescents in Europe: developments over 20 years and future challenges
    K Pritchard-Jones
    Section of Paediatric Oncology, Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK
    Eur J Cancer 42:2183-90. 2006
    ..Survival rates increased for nearly all types of cancer in children and adolescents. The implications of these findings for aetiological factors and treatment delivery for cancer in children and adolescents are discussed...
  8. ncbi request reprint In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line
    H A Cocker
    CRC Centre for Cancer Therapeutics, The Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom
    Clin Cancer Res 7:3193-8. 2001
    ..These experiments strongly suggest that the development of MDR may be preventable using modulators of MDR and merit clinical studies to test this hypothesis...
  9. ncbi request reprint Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour
    R Natrajan
    Paediatric Oncology, Institute of Cancer Research Royal Marsden NHS Trust, Sutton, UK
    J Pathol 211:52-9. 2007
    ..The two subsequent relapses in the left kidney contained an accumulation of additional genetic alterations, including an independent WT1 mutation...
  10. pmc Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma
    J Anderson
    Section of Paediatric Oncology, Institute of Cancer Research, Sutton, Surrey, UK
    Neoplasia 1:340-8. 1999
    ..Moreover, in tumours with p57(KIP2) expression, there was no evidence for inactivating mutations, suggesting that p57(KIP2) is not a tumour suppressor in rhabdomyosarcoma...
  11. pmc PAX7 expression in embryonal rhabdomyosarcoma suggests an origin in muscle satellite cells
    N Tiffin
    Section of Paediatric Oncology, Institute of Cancer Research, Belmont, Sutton, Surrey SM2 5NG, UK
    Br J Cancer 89:327-32. 2003
    ..This is corroborated by the detection of MET (c-met) expression, a marker for the myogenic satellite cell lineage, in all RMS samples expressing wild-type PAX7...
  12. ncbi request reprint Complex patterns of chromosome 9 alterations including the p16INK4a locus in Wilms tumours
    R Natrajan
    Paediatric Oncology, Institute of Cancer Research Royal Marsden NHS Trust, Sutton, UK
    J Clin Pathol 61:95-102. 2008
    ..Previous data implicating genetic and epigenetic events on chromosome 9, including the CDKN2A/2B locus, as molecular predictors of Wilms tumour relapse, have been conflicting...
  13. ncbi request reprint Cytogenetic abnormalities in 42 rhabdomyosarcoma: a United Kingdom Cancer Cytogenetics Group Study
    T Gordon
    Section of Molecular Carcinogenesis, Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Med Pediatr Oncol 36:259-67. 2001
    ..There was no evidence for involvement of the PAX3/7-FKHR genes in ERMS, and cryptic involvement was found in some ARMS. There were no consistent chromosomal rearrangements associated with apparently translocation negative ARMS cases...
  14. ncbi request reprint Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance
    L King-Underwood
    Section of Paediatric Oncology, Institute of Cancer Research, Belmont, Sutton, Surrey, UK
    Blood 91:2961-8. 1998
    ..The relationship of WT1 mutation to chemoresistance merits further investigation...
  15. ncbi request reprint The Wilms tumour gene, WT1, in normal and abnormal nephrogenesis
    K Pritchard-Jones
    Section of Paediatric Oncology, Institute of Cancer Research Royal Marsden NHS Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    Pediatr Nephrol 13:620-5. 1999
    ..Recommendations for management of children suspected of having a WT1 mutation are discussed...
  16. ncbi request reprint Multifaceted dysregulation of the epidermal growth factor receptor pathway in clear cell sarcoma of the kidney
    Suzanne E Little
    Paediatric Oncology, Institute of Cancer Research Royal Marsden NHS Trust, Sutton, United Kingdom
    Clin Cancer Res 13:4360-4. 2007
    ..We sought to evaluate these variables in pediatric renal tumors...
  17. pmc Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?
    J Anderson
    Section of Paediatric Oncology, Institute of Cancer Research, Sutton, Surrey, UK
    Br J Cancer 85:831-5. 2001
    ..This hypothesis requires testing in a prospective study. Variant t(1;13)/PAX7-FKHR appears biologically different, occurring in younger patients with more localised disease...
  18. pmc Controversies and advances in the management of Wilms' tumour
    K Pritchard-Jones
    The Institute of Cancer Research Royal Marsden Hospital, Section of Paediatric Oncology, Sutton, Surrey, UK
    Arch Dis Child 87:241-4. 2002
    ..The proportion of children with heritable disease is uncertain and there remains a need to collect data on the need for screening in this susceptible population...
  19. ncbi request reprint A novel and consistent amplicon at 13q31 associated with alveolar rhabdomyosarcoma
    A T Gordon
    Molecular Cytogenetics Laboratory, Institute of Cancer Research, Sutton, Surrey, UK
    Genes Chromosomes Cancer 28:220-6. 2000
    ..This indicates that a gene or genes at 13q31 are significant in the development or progression of alveolar rhabdomyosarcoma...
  20. pmc MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas
    E Missiaglia
    Molecular Cytogenetics Team, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    Br J Cancer 102:1769-77. 2010
    ..Our aim was to determine the effects of microRNAs (miRNA) that have been implicated in muscle development on the clinical behaviour of RMSs...
  21. ncbi request reprint Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors
    Rachael Natrajan
    Paediatric Oncology, Institute of Cancer Research Royal Marsden NHS Trust, Sutton, Surrey, United Kingdom
    Clin Cancer Res 12:7284-93. 2006
    ..We have previously shown a link between genomic gain of chromosome 1q and tumor relapse and sought to further elucidate the role of genes on 1q in treatment failure...
  22. pmc c-KIT overexpression, without gene amplification and mutation, in paediatric renal tumours
    Chris Jones
    Paediatric Oncology, Institute of Cancer Research Royal Marsden NHS Trust, Sutton, UK
    J Clin Pathol 60:1226-31. 2007
    ..To investigate the presence and prognostic relevance of KIT expression in paediatric renal tumours, and to determine whether receptor overexpression is associated with gene amplification and/or mutation...
  23. doi request reprint Efficacy and tolerability of high-dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children
    Mary M Taj
    Department of Paediatric Oncology, Royal Marsden Hospital, Sutton, Surrey, UK
    Br J Haematol 140:191-6. 2008
    ..Proof of effectiveness as a single agent in CNS lymphoma needs further studies...
  24. doi request reprint Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study
    Boo Messahel
    The Institute of Cancer Research, Section of Paediatric Oncology, Belmont, Sutton, Surrey, UK
    Eur J Cancer 45:819-26. 2009
    ..Its relationship with histological risk groups defined after neo-adjuvant chemotherapy requires analysis in a larger series, and is the subject of the current SIOP WT 2001 trial...
  25. ncbi request reprint Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines
    Richard D Williams
    Section of Paediatric Oncology, Institute of Cancer Research, Sutton, Surrey, UK
    Genes Chromosomes Cancer 41:65-79. 2004
    ..This set of discriminators was highly enriched in genes on 1q, indicating close agreement between data obtained from expression profiling with data from genomic copy number analyses...
  26. pmc Evidence for susceptibility genes to familial Wilms tumour in addition to WT1, FWT1 and FWT2
    E A Rapley
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
    Br J Cancer 83:177-83. 2000
    ....
  27. pmc Comparative expressed sequence hybridization to chromosomes for tumor classification and identification of genomic regions of differential gene expression
    Y J Lu
    Molecular Cytogenetics, Institute of Cancer Research, Sutton, Surrey SM2 5NG, United Kingdom
    Proc Natl Acad Sci U S A 98:9197-202. 2001
    ..The distinctive CESH profiles demonstrated in different subtypes of RMS show potential for tumor classification...
  28. pmc High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance
    H A Cocker
    CRC Centre for Cancer Therapeutics, The Institute of Cancer Research, Cotswold Road, Sutton, Surrey, SM2 5NG, UK
    Br J Cancer 85:1746-52. 2001
    ..The resistance was reversible using the MDR modulator PSC833, confirming the presence of P-glycoprotein. We conclude that MDM2 overexpression may be a mechanism by which multidrug resistance is regulated in some rhabdomyosarcomas...
  29. ncbi request reprint Case of interstitial 12q deletion in association with Wilms tumor
    E A Rapley
    Institute of Cancer Research, Section of Cancer Genetics, Haddow Labs, 15 Cotswold Road, Sutton, Surrey, SM6 8RW, UK
    Am J Med Genet 104:246-9. 2001
    ..In both families WT did not segregate with chromosome 12q markers located within the deletion boundaries...
  30. pmc Expression of hepatocyte growth factor and its receptor met in Wilms' tumors and nephrogenic rests reflects their roles in kidney development
    Raisa Vuononvirta
    Paediatric Oncology, Institute of Cancer Research Royal Marsden NHS Trust, Surrey, UK
    Clin Cancer Res 15:2723-30. 2009
    ..Despite this, an understanding of the HGF/Met axis in the process is lacking...
  31. doi request reprint Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor
    Richard D Williams
    Section of Paediatric Oncology, Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Clin Cancer Res 16:2036-45. 2010
    ....
  32. pmc BIRICODAR (VX-710; Incel): an effective chemosensitizer in neuroblastoma
    T Yanagisawa
    Section of Paediatrics, The Institute of Cancer Research Royal Marsden NHS Trust, Sutton, Surrey, UK
    Br J Cancer 80:1190-6. 1999
    ..These data confirm MDR1 and MRP expression as contributory factors in chemoresistance in neuroblastoma and indicate that VX-710 may be a useful modulator of both mechanisms and worthy of clinical evaluation in this tumour...
  33. ncbi request reprint Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse
    R Natrajan
    Paediatric Oncology, Institute of Cancer Research Royal Marsden NHS Trust, Sutton, Surrey SM2 5NG, UK
    J Pathol 210:49-58. 2006
    ..These data provide a high-resolution catalogue of genomic copy number changes in relapsing favourable histology Wilms tumours...
  34. ncbi request reprint A prospective study of admissions for febrile neutropenia in secondary paediatric units in South East England
    C Duncan
    Children s Unit, Royal Marsden Hospital, Sutton, United Kingdom
    Pediatr Blood Cancer 49:678-81. 2007
    ..This study evaluated the adherence to current guidelines for febrile neutropenia (FN) and documented outcome in terms of bacterial isolates, antibiotic resistance patterns, length of hospital stay, and mortality...
  35. pmc Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma
    K Pritchard-Jones
    Royal Marsden Hospital and Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 92:1358-65. 2005
    ..Future clinical trials incorporating immune stimulation strategies should include early introduction of vaccines during the highest risk period for relapse...
  36. ncbi request reprint EVE/cyclosporin (etoposide, vincristine, epirubicin with high-dose cyclosporin)-chemotherapy selected for multidrug resistance modulation
    A Davidson
    Children s Department, Royal Marsden NHS Trust Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK
    Eur J Cancer 38:2422-7. 2002
    ..We conclude that this combination is tolerable in heavily pretreated patients and may be suitable for further evaluation in untreated poor risk tumours...
  37. pmc Surveillance for Wilms tumour in at-risk children: pragmatic recommendations for best practice
    R H Scott
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
    Arch Dis Child 91:995-9. 2006
    ....
  38. doi request reprint Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development
    Edoardo Missiaglia
    Molecular Cytogenetics Team, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    Genes Chromosomes Cancer 48:455-67. 2009
    ....
  39. ncbi request reprint Delineation of a 1Mb breakpoint region at 1p13 in Wilms tumors by fine-tiling oligonucleotide array CGH
    Rachael Natrajan
    Paediatric Oncology, Institute of Cancer Research Royal Marsden NHS Trust, Sutton, UK
    Genes Chromosomes Cancer 46:607-15. 2007
    ..This study highlights the power of fine-tiling oligonucleotide arrays to delineate breakpoint regions identified by genome-wide screens...
  40. pmc Perilobar nephrogenic rests are nonobligate molecular genetic precursor lesions of insulin-like growth factor-II-associated Wilms tumors
    Raisa Vuononvirta
    Paediatric Oncology, Institute of Cancer Research Royal Marsden NHS Trust, Sutton, United Kingdom
    Clin Cancer Res 14:7635-44. 2008
    ..The precise genomic events are, however, largely unknown...
  41. ncbi request reprint Role for amplification and expression of glypican-5 in rhabdomyosarcoma
    Daniel Williamson
    Molecular Cytogenetics Team, Paediatric Oncology, Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Cancer Res 67:57-65. 2007
    ..Furthermore, the properties of GPC5 make it an attractive target for therapeutic intervention in rhabdomyosarcomas and other tumors that amplify and/or overexpress the gene...
  42. ncbi request reprint Frequency and heritability of WT1 mutations in nonsyndromic Wilms' tumor patients: a UK Children's Cancer Study Group Study
    Suzanne E Little
    Paediatric Oncology Unit, The Royal Marsden NHS Trust, Downs Rd, Sutton, Surrey, SM2 5PT United Kingdom
    J Clin Oncol 22:4140-6. 2004
    ..We sought to ascertain the frequency and heritability of constitutional WT1 mutations in nonsyndromic WT patients...
  43. ncbi request reprint Blastemal expression of type I insulin-like growth factor receptor in Wilms' tumors is driven by increased copy number and correlates with relapse
    Rachael Natrajan
    Paediatric Oncology, Institute of Cancer Research Royal Marsden National Health Service Trust, Sutton, UK
    Cancer Res 66:11148-55. 2006
    ..These findings suggest the possibility of use of targeted agents in the therapy of these children...
  44. doi request reprint Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumor
    Richard H Scott
    Section of Cancer Genetics, Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, SM2 5NG, UK
    Nat Genet 40:1329-34. 2008
    ..The impact on clinical management dictates that constitutional 11p15 analysis should be considered in all individuals with Wilms tumor...
  45. ncbi request reprint MIB-1 and p27Kip1 expression in nephroblastoma
    Chris Jones
    Clin Cancer Res 10:7785-6; author reply 7786. 2004
  46. ncbi request reprint Expression profiling targeting chromosomes for tumor classification and prediction of clinical behavior
    Yong Jie Lu
    Molecular Cytogenetics, Section of Molecular Carcinogenesis, Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Genes Chromosomes Cancer 38:207-14. 2003
    ..CESH is independent of selecting sequences for interrogation and is a simple, rapid, and widely accessible approach to identify clinically useful differential expression...
  47. doi request reprint Second primary neoplasms in survivors of Wilms' tumour--a population-based cohort study from the British Childhood Cancer Survivor Study
    Aliki J Taylor
    Centre for Childhood Cancer Survivor Studies, Department of Public Health and Epidemiology, The University of Birmingham, Edgbaston, Birmingham, UK
    Int J Cancer 122:2085-93. 2008
    ..Continued follow-up of these survivors is important to monitor such late effects of treatment. It is also important to evaluate the risk of second primary neoplasms following more recent lower radiation dose treatment practices...
  48. ncbi request reprint UK childhood cancer survival falling behind rest of EU?
    Alan W Craft
    Institute of Child Health, Newcastle upon Tyne, UK
    Lancet Oncol 8:662-3. 2007
  49. doi request reprint Childhood papillary thyroid cancer as second malignancy after successful treatment of rhabdomyosarcoma
    Ramachandran Venkitaraman
    Acta Oncol 47:469-72. 2008
  50. ncbi request reprint Wilms' tumor with intracaval thrombus in the UK Children's Cancer Study Group UKW3 trial
    Anupam Lall
    Department of Pediatric Surgery, Royal Manchester Children s Hospital, M27 4HA Manchester, UK
    J Pediatr Surg 41:382-7. 2006
    ..To define the clinical characteristics and surgical management of intracaval involvement in patients enrolled in the UKW3 trial (1991-2001), which recommended elective preoperative chemotherapy for such cases...
  51. ncbi request reprint Incidence of and survival from Wilms' tumour in adults in Europe: data from the EUROCARE study
    Emmanuel Mitry
    Service d Hépatogastroentérologie et Oncologie Digestive, Centre Hospitalo Universitaire Ambroise Paré, AP HP, Faculté de Médecine Paris Ile de France Ouest et Université Versailles Saint Quentin, 92100 Boulogne, France
    Eur J Cancer 42:2363-8. 2006
    ..This may, at least partly, be explained by the rarity of this diagnosis. Prognosis may be improved by the use of specific treatment guidelines for nephroblastoma in adults...
  52. ncbi request reprint Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumour: results of a randomised trial (UKW3) by the UK Children's Cancer Study Group
    Christopher Mitchell
    Department of Pediatric Hematology Oncology, John Radcliffe Hospital, Oxford OX3 9DU, and UKCCSG Data Centre, University of Leicester, UK
    Eur J Cancer 42:2554-62. 2006
    ....
  53. ncbi request reprint Malignant renal tumours incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project
    Guido Pastore
    Childhood Cancer Registry of Piedmont, Cancer Epidemiology Unit of the Centre for Cancer Epidemiology and Prevention, CERMS and University of Torino, Torino, Italy
    Eur J Cancer 42:2103-14. 2006
    ..Further development and exploitation of the ACCIS database will benefit clinical management and aetiological studies...
  54. ncbi request reprint Characteristics and survival of 750 children diagnosed with a renal tumor in the first seven months of life: A collaborative study by the SIOP/GPOH/SFOP, NWTSG, and UKCCSG Wilms tumor study groups
    Marry M van den Heuvel-Eibrink
    Department of Pediatric Oncology Hematology Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Pediatr Blood Cancer 50:1130-4. 2008
    ..To review the clinical characteristics and survival of infants diagnosed with a primary renal tumor in the first 7 months of life...
  55. ncbi request reprint Expression profile of wild-type ETV6 in childhood acute leukaemia
    Naina Patel
    Children s Cancer Group, and Medical Oncology Unit, Cancer Research UK, St Bartholomew s and the London, Queen Mary School of Medicine and Dentistry, London, UK
    Br J Haematol 122:94-8. 2003
    ..These observations support the hypothesis that loss of ETV6 expression is a critical secondary event for leukaemogenesis in ETV6-CBFA2 ALL...
  56. ncbi request reprint WT1 expression does not disrupt myogenic differentiation in C2C12 murine myoblasts or in human rhabdomyosarcoma
    Nicki Tiffin
    Section of Paediatric Oncology, Institute of Cancer Research, 15 Cotswold Road, Belmont, Sutton, SM2 5NG, Surrey, UK
    Exp Cell Res 287:155-65. 2003
    ..We conclude that expression of WT1 in C(2)C(12) cells and in rhabdomyosarcoma does not inhibit myogenic differentiation...
  57. ncbi request reprint Chromosome 1q expression profiling and relapse in Wilms' tumour
    Yong Jie Lu
    Section of Paediatrics, Institute of Cancer Research and Royal Marsden Hospital NHS Trust, Sutton, UK
    Lancet 360:385-6. 2002
    ..4-19960). This finding shows the value of CESH analysis to rapidly screen for chromosomal regions that carry genes whose differential expression is important in establishment of tumour behaviour...
  58. ncbi request reprint In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia
    Joseph L Wiemels
    Laboratory for Molecular Epidemiology, Department of Epidemiology and Biostatistics, University of California San Francisco 94143 0560, USA
    Blood 99:3801-5. 2002
    ....
  59. ncbi request reprint Chronic hepatotoxicity following 6-thioguanine therapy for childhood acute lymphoblastic leukaemia
    Barbara Piel
    Br J Haematol 125:410-1; author reply 412. 2004
  60. doi request reprint Long-term population-based risks of breast cancer after childhood cancer
    Raoul C Reulen
    Centre for Childhood Cancer Survivor Studies, Department of Public Health and Epidemiology, University of Birmingham, Edgbaston, Birmingham, United Kingdom
    Int J Cancer 123:2156-63. 2008
    ..Among women who survived to an age of at least 50 years there is currently no evidence of an increased risk of breast cancer...
  61. ncbi request reprint Clinical features of molecular pathology of solid tumours in childhood
    Boo Messahel
    Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK
    Lancet Oncol 6:421-30. 2005
    ..Tumour biology now plays an important part in identifying appropriate treatment through more accurate diagnoses and new risk stratifications based on molecular markers...
  62. ncbi request reprint Outcome after pulmonary radiotherapy in Wilms' tumor patients with pulmonary metastases at diagnosis: a UK Children's Cancer Study Group, Wilms' Tumour Working Group Study
    Gary Nicolin
    Department of Pediatric Hematology Oncology, John Radcliffe Hospital and University of Oxford, Oxford, United Kingdom
    Int J Radiat Oncol Biol Phys 70:175-80. 2008
    ....
  63. pmc Effect of media portrayals of removal of children's tissue on UK tumour bank
    Clive Seale
    School of Social Sciences and Law, Brunel University, Uxbridge, Middlesex UB8 3PH
    BMJ 331:401-3. 2005
  64. ncbi request reprint Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study
    Gareth J Veal
    Northern Institute for Cancer Research, University of Newcastle upon Tyne, UK
    Clin Cancer Res 11:5893-9. 2005
    ..Despite concerns over the incidence of toxicity, little is known about the pharmacology of dactinomycin. A study was done to investigate dactinomycin pharmacokinetics in children...
  65. ncbi request reprint Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA
    Suzanne E Little
    Paediatric Oncology, Institute of Cancer Research Royal Marsden NHS Trust, Sutton, Surrey SM2 5NG, UK
    Genomics 87:298-306. 2006
    ..918). This WGA method should readily lend itself to the determination of DNA copy number alterations from small fresh-frozen and FFPE clinical tumor specimens, although some care must be taken to optimize the DNA extraction procedure...
  66. ncbi request reprint Consent for childhood cancer tissue banking in the UK: the effect of the Human Tissue Act 2004
    Jean McHale
    Faculty of Law, University of Leicester, UK
    Lancet Oncol 8:266-72. 2007
    ....
  67. pmc Alternately spliced WT1 antisense transcripts interact with WT1 sense RNA and show epigenetic and splicing defects in cancer
    Anthony R Dallosso
    CLIC Sargent Research Unit, Department of Cellular and Molecular Medicine, School of Medical Sciences, University of Bristol, Bristol BS8 1TD, United Kingdom
    RNA 13:2287-99. 2007
    ..These results show that WT1 encodes conserved antisense RNAs that may have an important regulatory role in WT1 expression via RNA:RNA interactions, and which can become deregulated by a variety of mechanisms in cancer...